CBD Oil in Italian Pharmacies: What Is Legal in 2026

On 3 August 2026 the Council of State stopped deciding whether Italy could put oral CBD on the medicines table and asked Luxembourg instead. On 14 August the Lazio regional court, in two separate cases, rejected two more company appeals, one against the decree and one against the ministry's circular on cosmetics. The sector's own reading is that nothing has changed on the shelf. The pharmacists' federation reads the situation differently on flower-derived oils.

So what does an Italian pharmacy really sell under the name “olio CBD” in September 2026, and what should the label tell you? This guide sorts it. It is general information, not medical or legal advice.

Where does the 2024 decree stand, one court at a time?

The 14 August rulings led to headlines that CBD needs a prescription. Canapa Sativa Italia, a network of more than 400 hemp companies, told ANSA on 17 August that this is wrong: the suspension stands, and the Health Ministry has said the pharmacy control measures lapse while the decree is suspended. Farmacista33, the trade press, reported the same instruction to pharmacists after the December order: stop the vouchers, follow the pre-2024 regime.

What can a pharmacy legally give you today?

Two lessons follow. First, a bottle marked “CBD” sitting next to vitamins is not proof of anything. FOFI's line is that flower-derived oils and extracts can no longer be sold, and the circular puts CBD supplements outside food law. Second, the pharmacy is the only place where CBD is made to a documented standard, and it comes with a prescriber attached. The wider legal fight over flower is in our cannabis light explainer, and the court referral in the Council of State news item.

What do EMA, the ISS and EFSA say about side effects?

Italy's health institute (ISS) and the Higher Health Council issued updated opinions in May and June 2024. According to Farmacista33's summary, they stress that natural CBD is never entirely free of THC, that it can interact with other medicines, and that pharmacovigilance systems have flagged contamination with synthetic cannabinoids. Those opinions are the base for the ministry's caution. They do not, on that account, prove a psychoactive effect from CBD, which was the point the trade groups contested.

For hard numbers on a regulated product, look at the licensed medicine. EMA's public page for Epidyolex lists somnolence, decreased appetite, diarrhoea, fever, tiredness and vomiting as the most common effects, and raised liver enzymes as the commonest reason to stop treatment. It must not be used when liver enzymes are more than three times the normal limit with bilirubin above twice the limit. Treatment is started and supervised by a doctor experienced in epilepsy.

How to ask for it, and what to check

• A prescription with the substance named. A compounded preparation needs the doctor to write it and the pharmacist to accept it; ask before you go.
• The medicine's name and leaflet. Epidyolex comes with an official package leaflet; ask the pharmacy what a compounded product contains and who prepared it.
• No therapeutic promise. A retail oil that claims to treat a condition is behaving like an unlicensed medicine.
• The source of the CBD. Seed-derived, synthetic or flower-derived matters legally: only the first two sit outside Article 18.
• A lab certificate. Ask for the batch analysis with THC content; our COA guide shows the lines that matter.